• Robert Belvís, Pablo Irimia, Nuria González, Jésica García-Ull, Patricia Pozo-Rosich, Alba López-Bravo, Noemí Morollón, Sonia Quintas, Antoni Plana, Pablo Gregorio Baz, Ana Tentor, Natalia Gallego Artiles, Francisco Javier León, Miguel Pérez Martín, Inés Rivera, Raquel Ramírez, Isabel Colomina, José Miguel Lainez, and Julio Pascual.
• Unidad de Cefaleas y Neuralgias, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau. Grupo de Estudio de Cefaleas de la SEN, Barcelona, España. Electronic address: rbelvis@santpau.cat.
• Med Clin (Barc). 2024 Aug 30; 163 (4): 208.e1208.e10208.e1-208.e10.

AbstractMigraine is a disease with a high prevalence and incidence, in addition to being highly disabling, causing a great impact on the patient's quality of life at a personal, family and work level, but also social, given its high expense due to its direct (care) and indirect (presenteeism and work absenteeism) costs. The multiple and recent developments in its pathophysiological knowledge and in its therapy require updating and, therefore, in this article the Spanish scientific societies most involved in its study and treatment (SEN, SEMFYC and SEMERGEN), together with the Association Spanish Association for Patients with Migraine and other Headaches (AEMICE), we have developed these updated care recommendations. We reviewed the treatment of migraine attacks, which consisted mainly of the use of NSAIDs and triptans, to which ditans and gepants have been added. We also discuss preventive treatment consisting of oral preventive drugs, botulinum toxin, and treatments that block the action of calcitonin-related peptide (CGRP). Finally, we emphasize that pharmacological treatments must be complementary to carrying out general measures consisting of identifying and managing/deletion the precipitating factors of the attacks and the chronicizing factors, controlling the comorbidities of migraine and eliminating analgesic overuse.Copyright © 2024. Published by Elsevier España, S.L.U.

21 keywords...

hide…